Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development

被引:108
|
作者
Szabo, R. [1 ]
Molinolo, A. [1 ]
List, K. [1 ]
Bugge, T. H. [1 ]
机构
[1] Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA
关键词
placenta development; labyrinth formation; membrane proteolysis; trophoblast differentiation; basement membrane; protease inhibition;
D O I
10.1038/sj.onc.1209966
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hepatocyte growth factor activator inhibitor-1 (HAI-1) is a Kunitz-type transmembrane serine protease inhibitor that forms inhibitor complexes with several trypsin-like serine proteases and is required for mouse placental development and embryo survival. Here we show that the essential function of HAI-1 in placentation and all other embryonic processes is to restrict the activity of the type II transmembrane serine protease, matriptase. Enzymatic gene trapping of matriptase combined with HAI-1 immunohistochemistry revealed that matriptase is co-expressed with HAI-1 in both extraembryonic and embryonic tissues. As early as embryonic day 8.5, matriptase and HAI-1 were expressed in a population of chorionic trophoblasts. Ablation of HAI-1 disrupted the epithelial integrity of this cell population, causing disorganized laminin deposition and altered expression of E-cadherin and beta-catenin. This led to a complete loss of undifferentiated chorionic trophoblasts after embryonic day 9.5 and prevented the formation of the placental labyrinth. Genetic ablation of matriptase activity in HAI-1-deficient embryos, however, restored the integrity of chorionic trophoblasts and enabled placental labyrinth formation and development to term. Furthermore, matriptase/HAI-1 double-deficient mice were phenotypically indistinguishable from matriptase single-deficient litter-mates. Oncogene
引用
下载
收藏
页码:1546 / 1556
页数:11
相关论文
共 50 条
  • [21] Role of the Stem Domain of Matriptase in the Interaction with its Physiological Inhibitor, Hepatocyte Growth Factor Activator Inhibitor Type I
    Kojima, Kenji
    Tsuzuki, Satoshi
    Fushiki, Tohru
    Inouye, Kuniyo
    JOURNAL OF BIOCHEMISTRY, 2009, 145 (06): : 783 - 790
  • [22] Identification of the Matriptase Second CUB Domain as the Secondary Site for Interaction with Hepatocyte Growth Factor Activator Inhibitor Type-1
    Inouye, Kuniyo
    Tsuzuki, Satoshi
    Yasumoto, Makoto
    Kojima, Kenji
    Mochida, Seiya
    Fushiki, Tohru
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (43) : 33394 - 33403
  • [23] Matriptase Does Not Require Hepatocyte Growth Factor Activator Inhibitor Type-1 for Activation in an Epithelial Cell Expression Model
    Miyake, Yuka
    Tsuzuki, Satoshi
    Fushiki, Tohru
    Inouye, Kuniyo
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2010, 74 (04) : 848 - 850
  • [24] Hepatocyte growth factor and placental development
    Kilby, M
    Whittle, M
    Strain, A
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 174 (06) : 1946 - 1946
  • [25] Expression of hepatocyte growth factor activator inhibitor-1 (HAI-1) gene in prostate cancer: Clinical and biological significance
    Hu, Chuanyi
    Jiang, Ning
    Wang, Guozeng
    Zheng, Jingcun
    Yang, Wei
    Yang, Jiawei
    JOURNAL OF BUON, 2014, 19 (01): : 215 - 220
  • [26] Induction of plasminogen activator inhibitor-1 production by hepatocyte growth factor in liver and its potential clinical implications for angiogenesis
    Imagawa, S
    Fujii, S
    Jie, D
    Kaneko, T
    Goto, D
    Furumoto, T
    CIRCULATION, 2004, 110 (17) : 114 - 114
  • [27] Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro
    Sanders, Andrew J.
    Parr, Christian
    Mason, Malcolm D.
    Jiang, Wen G.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2007, 20 (04) : 613 - 619
  • [28] HEPATOCYTE GROWTH-FACTOR INCREASES PRODUCTION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN HEPG2 CELLS
    WOJTA, J
    NAKAMURA, T
    HUFNAGL, P
    BINDER, BR
    MCGRATH, K
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 608 - 608
  • [29] Hepatocyte growth factor activator inhibitor-2 resides primarily intracellularly to facilitate cell surface transport of matriptase
    Larsen, B. R.
    Steffensen, S. D. R.
    Nielsen, N. V. L.
    Friis, S.
    Godiksen, S.
    Bornholdt, J.
    Sondergaard, C.
    Andersen, M. N.
    Poulsen, S. S.
    Szabo, R.
    Bugge, T. H.
    Lin, C. Y.
    Skovbjerg, H.
    Jensen, J. K.
    Vogel, L. K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (06) : E18 - E18
  • [30] Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer
    Kang, JY
    Dolled-Filhart, M
    Ocal, IT
    Singh, B
    Lin, CY
    Dickson, RB
    Rimm, DL
    Camp, RL
    CANCER RESEARCH, 2003, 63 (05) : 1101 - 1105